Literature DB >> 25056393

Interpreting the CYP2D6 results from the International Tamoxifen Pharmacogenetics Consortium.

M A Province1, R B Altman2, T E Klein2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25056393      PMCID： PMC4147833          DOI： 10.1038/clpt.2014.100

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  2 in total

1.  Avoiding the high Bonferroni penalty in genome-wide association studies.

Authors:  Xiaoyi Gao; Lewis C Becker; Diane M Becker; Joshua D Starmer; Michael A Province
Journal:  Genet Epidemiol       Date:  2010-01       Impact factor: 2.135

2.  CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Authors:  M A Province; M P Goetz; H Brauch; D A Flockhart; J M Hebert; R Whaley; V J Suman; W Schroth; S Winter; H Zembutsu; T Mushiroda; W G Newman; M-T M Lee; C B Ambrosone; M W Beckmann; J-Y Choi; A-S Dieudonné; P A Fasching; R Ferraldeschi; L Gong; E Haschke-Becher; A Howell; L B Jordan; U Hamann; K Kiyotani; P Krippl; D Lambrechts; A Latif; U Langsenlehner; W Lorizio; P Neven; A T Nguyen; B-W Park; C A Purdie; P Quinlan; W Renner; M Schmidt; M Schwab; J-G Shin; J C Stingl; P Wegman; S Wingren; A H B Wu; E Ziv; G Zirpoli; A M Thompson; V C Jordan; Y Nakamura; R B Altman; M M Ames; R M Weinshilboum; M Eichelbaum; J N Ingle; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2013-09-23       Impact factor: 6.875
  2 in total
  5 in total

Review 1.  Essential Characteristics of Pharmacogenomics Study Publications.

Authors:  Caroline F Thorn; Michelle Whirl-Carrillo; Houda Hachad; Julie A Johnson; Ellen M McDonagh; Mark J Ratain; Mary V Relling; Stuart A Scott; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01       Impact factor: 6.875

Review 2.  Pharmacogenomics in the clinic.

Authors:  Mary V Relling; William E Evans
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

Review 3.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102

4.  CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.

Authors:  Per Damkier; Anders Kjærsgaard; Kimberly A Barker; Deidre Cronin-Fenton; Anatasha Crawford; Ylva Hellberg; Emilius A M Janssen; Carl Langefeld; Thomas P Ahern; Timothy L Lash
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

5.  Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen.

Authors:  Thomas Helland; Bjørn Naume; Steinar Hustad; Ersilia Bifulco; Jan Terje Kvaløy; Anna Barbro Saetersdal; Marit Synnestvedt; Tone Hoel Lende; Bjørnar Gilje; Ingvil Mjaaland; Kjetil Weyde; Egil Støre Blix; Gro Wiedswang; Elin Borgen; Daniel Louis Hertz; Emiel Adrianus Maria Janssen; Gunnar Mellgren; Håvard Søiland
Journal:  Mol Oncol       Date:  2020-12-14       Impact factor: 6.603
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.